The rate of growth in retail current value sales of cough, cold and allergy (hay fever) remedies will slow slightly but remain robust in 2025. Demand for cough and cold remedies continues to be bolstered by high transmission rates for the common cold and flu.

Retail value sales are rising for cough, cold and allergy (hay fever) remedies in the Philippines in 2025. As in-person interactions increase, exposure to allergens in public spaces has intensified. This shift, influenced by the commercialisation of social events, has led to a noticeable rise in demand for allergy relief products.

Cough, cold, and allergy (hay fever remedies) is expected to register healthy current value growth in Tunisia in 2025. A cold winter supports value sales, as it leads to higher incidence of colds and flus. Increasing local offerings also supports value sales, with several new brands launched that are more affordable than many imported offerings. These are mainly in the herbal/traditional segment, as these can avoid price regulation. Medicated confectionery is expected to register the highest val

Value sales of cough, cold and allergy (hay fever) remedies are increasing in New Zealand in 2025, driven mainly by combination products, which is the fastest-rising subcategory. Combination products has performed solidly in both 2024 and 2025, following the decision to return pseudoephedrine to New Zealand pharmacies.

Value sales of cough, cold and allergy (hay fever) remedies in Nigeria continue to rise in 2025, supported by stabilising unit prices after the steep increases recorded in 2024. Although prices remain high, inflation and currency depreciation have eased slightly, allowing the category to recover in volume terms following a contraction in 2024.

2025 is seeing value sales of cough, cold and allergy (hay fever) remedies increase in 2025, thanks to consumers’ heightened sensitivity to respiratory health and their preference for early intervention. Singaporeans continue to respond proactively to cough and cold symptoms, purchasing treatments promptly to prevent escalation. A wide range of formats, including nasal sprays, cough syrups and nasal decongestant drops, ensures easy accessibility and convenience for consumers managing mild or ear

Value sales of cough, cold and allergy (hay fever) remedies increased in 2025, with the self-medication trend continuing to support healthy growth. Instead of paying consultation fees, consumers increasingly prefer to purchase OTC remedies from pharmacies where they can also get professional advice for less serious illnesses. The quick relief these products provide for common symptoms and their wide availability and accessibility further drive their appeal.

Cough, cold and allergy (hay fever) remedies in Spain is projected to see strong retail current value growth over 2025, albeit continuing to slow compared with the dynamic increases recorded in 2022 and 2023. As in previous years of the review period, the performance of the category is linked to the incidences of influenza and cold outbreaks and lingering cases of COVID-19. Compared with COVID-19 and the subsequent return to normality, the incidence of flu and cold cases has been weaker in 2025.

Current value sales of cough, cold and allergy (hay fever) remedies increased in 2025, mainly due to a severe cold and flu season combined with greater consumer awareness about managing allergies. Pharyngeal preparations experienced the most notable increase, reflecting trends toward products addressing multiple symptoms.

In 2025, cough, cold and allergy remedies in Italy shows a mixed performance. Products for respiratory and flu-related conditions recorded significant growth, driven by a particularly intense and prolonged flu season. With over 16 million estimated cases, 2024-2025 stood out as one of the worst flu seasons in recent years, with the peak falling in late January and early February. This scenario sustained demand for flu remedies, pushing sales well above expectations. By contrast, antihistamines/a

Retail current value sales of cough, cold and allergy (hay fever) remedies in South Africa are projected to continue to see further strong growth over 2025, supported by retail volume sales rises amidst robust inflationary pressure on prices. The main categories include cough remedies, combination products, decongestants, medicated confectionery and pharyngeal preparations. Albeit from a low base, decongestant rubs is recording particularly dynamic retail volume growth at the end of the review p

Cough, cold and allergy (hay fever) remedies in North Macedonia is poised to register robust growth in total current value sales in 2025, while all categories are set to show similarly solid performances in volume terms. Along with the self-medication trend, weather conditions have had a positive impact on overall demand. Specifically, the peak period for the spread of seasonal respiratory viruses was prolonged by a colder than usual start to spring, with a hotter and drier than average summer s

Retail value sales of cough, cold and allergy (hay fever) remedies are set to rise in current terms in Indonesia in 2025. This growth is being driven by several factors, including the return of respiratory infections following the easing of pandemic restrictions, greater exposure to outdoor allergens due to urban expansion, and rising health consciousness post-COVID, which has encouraged consumers to treat symptoms early. The volatile weather patterns and increasing air pollution in cities such

Sales of cough, cold and allergy (hay fever) remedies have seen only moderate growth in current value terms in 2025. This slow growth is mainly due to the withdrawal of pseudoephedrine-based combination products, following safety concerns. Pseudoephedrine has been linked to serious health risks, prompting its removal from OTC availability. As a result, sales of combination products – cough, cold and allergy (hay fever) remedies have plummeted in 2025, with sales now being a fraction of what they

Value sales of cough, cold and allergy (hay fever) remedies in Hong Kong are seeing a notable increase in 2025 as the city navigates the challenges posed by recurring influenza outbreaks throughout the year. The interplay of various respiratory illnesses, notably exacerbated by the COVID-19 pandemic, has created a heightened demand for effective remedies. The spike in COVID-19 cases observed in late spring coincided with the hay fever season, which typically peaks during this same period, furthe

Value sales of cough, cold and allergy (hay fever) remedies have increased in 2025 in current terms. Demand is being fuelled in part by an increase in pollution and climate-related allergies which is driving demand for antihistamines/allergy remedies and nasal sprays in particular. Worsening environmental conditions linked to climate change and air pollution is leading towards a growing prevalence of respiratory issues in children as well as heightened parental awareness/concern among Thais. Dem

2025 is seeing a slight fall in value sales for cough, cold and allergy (hay fever) remedies in Saudi Arabia. However, combination cough, cold and allergy remedies is posting double-digit growth and outpacing all other category members. This is mainly thanks to the return of previously unavailable key products to shelves, though sales are also being pushed by consumer demand for convenient, multi-symptom relief. The segment is further supported by improved supply chain stability, strategic resto

The rate of growth in retail current value sales of cough, cold, and allergy remedies in Uzbekistan slowed significantly but remained in double digits in 2025. However, this growth was largely driven by inflation. Moreover, a shortened cold season limited overall consumption. In April 2025, the introduction of a 23% VAT on medicines led to higher retail prices, boosting value sales even as fewer units were sold. Additionally, new Good Pharmacy Practice (GPP) standards raised operational costs fo

Cough, cold and allergy (hay fever) remedies is expected to register moderate current value growth in Portugal in 2025. New viruses that are resistant to antibiotics support value sales. In addition, an ageing population which takes longer to recover from colds and coughs, also supports value sales. Also, as the public health system is under increasing pressure, with services more difficult to access, consumers increasingly self-medicate. In 2025, combination products are expected to register

Value sales of cough, cold and allergy (hay fever) remedies increased in Greece in 2025, although growth slowed compared to 2024. Volume growth was notably modest across most categories, reflecting the absence of a significant surge in illness during the year. The increase in value was primarily driven by retail price hikes among leading brands.

Cough, cold and allergy (hay fever) remedies is recording solid value growth in Malaysia in 2025, as local consumers continue to take proactive steps in managing respiratory health. Ongoing risks from COVID-19 and influenza cases maintain demand, while generic options are also seeing rising uptake, driven by affordability and accessibility.

The market for cough, cold, and allergy remedies in Uruguay will continue to expand in current value terms in 2025, supported by a more favourable economic environment and climate-related factors. Warmer weather during the first half of the year, combined with increased outdoor activity, has contributed to stronger-than-expected growth for systemic antihistamines/allergy remedies.

Sales of cough, cold and allergy (hay fever) remedies have seen continued growth in 2025 in current value terms. This has been partly driven by strong growth in antihistamines/allergy remedies. As Danish consumers spend more time outside, and the allergy season becomes longer due to the impact of climate change, the number of Danes suffering with allergies is also increasing.

In 2025, cough, cold and allergy (hay fever) remedies in Slovakia is returning to steady growth in retail value, following the turbulence of earlier shortages. Although lingering supply gaps and inflationary pressures still shape consumer behaviour, purchasing patterns are becoming more stable. The recovery is strongly supported by improved availability of antihistamines/allergy remedies and rising demand for nasal sprays and oral decongestants.